Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study

Tetar, S.; Bruynzeel, A.; Oei, S.S.; Senan, Suresh; Fraikin, Tamara; Slotman, B.J.; Moorselaar, R. Jeroen A. van; Lagerwaard, Frank J.

doi:10.1016/j.euo.2020.05.007

Cited by 50 publications

(49 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data were recently updated with a final PROMs analysis after one year of follow-up, which confirmed the absence of G ≥ 3 adverse events. Furthermore, at 12 months after the end of treatment, QoL returned to baseline conditions, with only 2% of patients reporting persistent bowel symptoms [33].…”

Section: Mr-guided Radiotherapy: Present Evidencementioning

confidence: 92%

“…For both devices, given the relatively longer treatment time per session, the simulation process is a crucial factor in order to perform an accurate and refined treatment delivery. Based on available literature, most experiences reported a similar protocol in terms of bladder filling and rectal emptying ( [32][33][34][35][36][37][38]-see Table 1). For both the CT scan (performed for dose calculation purposes) and the MRI scan, patients were educated to have a half-full bladder in order to take into account residual volume changes during the plan adaptation phase (Figure 2).…”

Section: Mr-guided Radiotherapy: Present Evidencementioning

confidence: 99%

See 1 more Smart Citation

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer

Cuccia

Corradini

Mazzola

et al. 2021

Cancers

View full text Add to dashboard Cite

In this review we summarize the currently available evidence about the role of hybrid machines for MR-guided radiotherapy for prostate stereotactic body radiotherapy. Given the novelty of this technology, to date few data are accessible, but they all report very promising results in terms of tolerability and preliminary clinical outcomes. Most of the studies highlight the favorable impact of on-board magnetic resonance imaging as a means to improve target and organs at risk identification with a consequent advantage in terms of dosimetric results, which is expected to relate to a more favorable toxicity pattern. Still, the longer treatment time per session may potentially affect the patient’s compliance to the treatment, although first quality of life assessment studies have reported substantial tolerability and no major impact on quality of life. Finally, in this review we hypothesize some future scenarios of further investigation, based on the possibility to explore the superior anatomy visualization and the role of daily adapted treatments provided by hybrid MR-Linacs.

show abstract

Section: Mr-guided Radiotherapy: Present Evidencementioning

confidence: 92%

Section: Mr-guided Radiotherapy: Present Evidencementioning

confidence: 99%

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer

Cuccia

Corradini

Mazzola

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Tetar et al ( 49 ) recently provided an update on the VU series with toxicity information extending through one year of follow-up. No grade 3 or higher toxicities were reported.…”

Section: Published Literature On Prostate Mrgrtmentioning

confidence: 99%

MR-Guided Radiotherapy for Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anatomical information to improve organ delineation. MR-guided radiotherapy, with daily re-planning, has shown early promise in the accurate delivery of radiotherapy. In this article, we discuss the shortcomings of current image-guidance strategies and the potential benefits and limitations of MR-guided treatment for prostate cancer. We also recount present experiences of MR-linac workflow and the opportunities afforded by this technology.

show abstract

“…The recent introduction of integrated magnetic resonance (MR) linear accelerators (linacs) into clinical practice has opened new perspectives for radiation therapy (RT), offering the advantages of coupling 0.35 or 1.5 T on-board MR scanners firstly with a triplet of 60 Co heads and later with 6 and 7 MV linacs in stand-alone hybrid units ( 1 – 3 ). MR guided radiotherapy (MRgRT) has been successfully applied to several anatomical sites, exploiting online adaptive planning solutions and innovative motion management, with improved dosimetric performance and early clinical results suggesting improved efficacy and toxicity reduction ( 4 – 6 ). Despite the numerous explored applications, the published clinical evidence is still scarce, and the actual quantification of the advantages of using such an advanced technology is still the object of debate in the radiation oncology community ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

MR-Guided Radiotherapy for Liver Malignancies

et al. 2021

View full text Add to dashboard Cite

MR guided radiotherapy represents one of the most promising recent technological innovations in the field. The possibility to better visualize therapy volumes, coupled with the innovative online adaptive radiotherapy and motion management approaches, paves the way to more efficient treatment delivery and may be translated in better clinical outcomes both in terms of response and reduced toxicity. The aim of this review is to present the existing evidence about MRgRT applications for liver malignancies, discussing the potential clinical advantages and the current pitfalls of this new technology.

show abstract

Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study

Cited by 50 publications

References 24 publications

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer

MR-Guided Radiotherapy for Prostate Cancer

MR-Guided Radiotherapy for Liver Malignancies

Contact Info

Product

Resources

About